New Insights in ALK+ Lung Cancer Treatment: Promising Results From the ALEK-B trial – Oncogene Cancer Research
Oncogene Cancer Research shared on LinkedIn about a recent paper by Oscar Arrieta et al. published in Nature Communications:
“New insights in ALK+ lung cancer treatment: promising results from the ALEK-B trial
The ALEK-B phase 2 study, recently published in Nature Communications, explores a novel first-line combination of alectinib and bevacizumab in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC). The results are noteworthy:
- 100% overall response rate
- 12-month PFS of 97.1%
- Median PFS of 39.6 months (95% CI: 27.2–not reached)
- 36-month intracranial PFS of 87.8%
- Improved quality of life reported despite grade 3–4 events in 46% of patients
While alectinib monotherapy already sets a high bar with ~34 months median PFS, this combination may offer further benefit – especially for patients with high-risk features like ALK variant 3 or CNS involvement.
Kudos to the authors for pushing the field forward, including Drs Oscar Arrieta, Remon Jordi, Eduardo Rios-Garcia, Luis Antonio Lara Mejía, Luis Antonio Cabrera Miranda, David Davila Dupont, Alexandra Garcilazo Reyes and Dr. Rafael Rosell Rosell.
As we strive for longer, better lives for people with ALK+ NSCLC, combinations like this may hold promise—particularly in subgroups where resistance remains a challenge.”
Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial
Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell
More about Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023